70403-11-1

Basic information

• Product Name: 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile
• Synonyms: 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile
• CAS NO: 70403-11-1
• Molecular Weight: 305.423
• Mol File: 70403-11-1.mol

Chemical Properties

• CAS DataBase Reference: 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile(70403-11-1)
• EPA Substance Registry System: 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile(70403-11-1)

Safety Data

• Hazardous Substances Data: 70403-11-1(Hazardous Substances Data)

Usage

Structure

Piperazine derivative with two benzyl groups and an acetonitrile group attached

Potential applications

Medicinal chemistry, drug development, building block for synthesis of other organic compounds, starting material for new drugs or therapeutic agents

Chemical and physical properties

Not extensively studied, but likely to exhibit characteristics common to similar piperazine derivatives such as solubility in organic solvents and compatibility with various reaction conditions.

Upstream product

• 143-33-9 sodium cyanide 
• 24225-89-6 2-chloromethyl-1,4-bis(phenylmethyl)piperazine 
• 25109-74-4 3,4-dibromobutyronitrile 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 42879-03-8 4-bromobut-2-enenitrile 
• 122-75-8 N,N'-dibenzylethylenediamine diacetate 
• 5700-61-8 N,N'-di(phenylethyl)ethylenediamine 
• 109-75-1 but-3-enenitrile 
• 94437-04-4 1,4-dibenzyl-2-hydroxypiperazine 
• 72351-59-8 ethyl 1,4-dibenzylpiperazin-2-carboxylate 
• 151-50-8 potassium cyanide 

Downstream Products

• 162510-50-1 ethyl (1,4-dibenzylpiperazin-2-yl)acetate 
• 25143-13-9 Centperazine 
• 151733-63-0 2-methyl-octahydro-6H-pyrazino<1,2-c>pyrimidin-6-one 
• 151733-60-7 ethyl N-<2-(1,4-dibenzyl-2-piperazinyl)ethyl>carbamate 
• 2465-79-4 2-(piperazin-2-yl)acetonitrile 
• 2158301-19-8 (±)-2-piperazin-2-ylacetonitrile dihydrochloride 

Relevant articles and documents

KRAS MUTANT PROTEIN INHIBITORS

The invention relates to a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.

Cycloalkyl and heterocycloalkyl inhibitors as well as preparation method and application thereof

The invention relates to cycloalkyl and heterocycloalkyl inhibitors as well as a preparation method and application thereof. Specifically, the compounds disclosed by the invention have a structure as shown in a formula (I). The invention also discloses a preparation method of the compounds and application of the compounds as KRASG12C inhibitors. The compounds have a good selective inhibition effect on KRASG12C, and have better pharmacodynamic and pharmacokinetic properties and lower toxic and side effects.

SPIROCYCLIC TETRAHYDROQUINAZOLINES

Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KRAS inhibitors and are thus useful to treat cancer and other diseases.

Spirocyclic tetrahydroquinazolines

The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Tetrahydropyrido[3,4-d]pyrimidine-2-(1H)-ketone compound as well as preparation method and medical application thereof

The invention discloses a tetrahydropyrido[3,4-d]pyrimidine-2-(1H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salt, stereoisomer, solventcompound or prodrug thereof, the compound is shown as a

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.